Market Overview

UPDATE: Pareto Securities Downgrades AstraZeneca to Sell

Related AZN
Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'
A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision

Pareto Securities reduced its rating on AstraZeneca (NYSE: AZN) from Hold to Sell and lowered its price target from $48 to $44.

Pareto Securities noted, "AstraZeneca (AZN) did not surprise on revenues although margins overall were stronger than consensus expectations. The appointment of a new CEO and recent deals have lifted the valuation to new highs. We do not believe this is sustainable in the short term as 2013E numbers are not strong enough."

AstraZeneca closed at $46.70 on Thursday.

Latest Ratings for AZN

Jul 2017Morgan StanleyDowngradesOverweightEqual-Weight
Jul 2017Leerink SwannDowngradesOutperformMarket Perform
May 2017Credit SuisseUpgradesUnderperformNeutral

View More Analyst Ratings for AZN
View the Latest Analyst Ratings

Posted-In: Pareto SecuritiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (AZN)

View Comments and Join the Discussion!